← MyAIGuide.ProMyAIGuide Weekly · Issue 3 · Sep 21–27, 2026

This browser cannot render the magazine pages. Open the text version

Money & Markets

Money & Markets

Big money is flowing into AI infrastructure and drug discovery, while the market's appetite for pure tech plays is shifting. Here's what moving this week.

  1. 1
    Basecamp Research Raises $140M Series C to Train New EDEN Models

    Basecamp Research's $140M raises stakes in AI-designed drugs—watch this space if your company bets on biotech innovation or supply chain pharma. · AI Funding & Investments

  2. 2
    Finnish AI cloud startup Verda raises $189 million Series B, crossing $1 billion valuation

    Verda's $1B+ valuation shows AI cloud infrastructure is now a serious investment category; consider whether your current cloud vendor is keeping pace. · AI Funding & Investments

  3. 3
    Neocloud Nscale Raises $3.36B in New Funding

    Neocloud Nscale's $3.36B haul signals institutional money is consolidating around fewer, larger AI plays—your vendor choices may narrow. · AI Funding & Investments

  4. 4
    AI Drug Discovery Firm Iambic Therapeutics Plans Nasdaq Debut With Nvidia Backing

    Iambic's Nasdaq filing and Nvidia backing confirm AI drug discovery is crossing into mainstream finance; healthcare teams should track this sector. · AI Mergers & Acquisitions

  5. 5
    One key part of the AI trade has decoupled from the rest. Why that is, and whether it can come back

    Industrial stocks outpacing AI stocks suggests the trade may be maturing; investors are rotating from hype into actual deployed applications. · AI in Finance

MyAIGuide.Pro · A CloudOMax product · SuperIntelligence, blissfully yours. · © 2026 CloudOMax Corp. All rights reserved.

7 / 16

MyAIGuide Weekly · Issue 3

Meta's massive AI bets are finally moving the needle on stock price. But shareholders want proof the company can actually profit from them.

Prefer a list? Read as text · RSS